

VI Congresso Nazionale di Ecocardiochirurgia

MILANO, 15-17/10/2012

Le cardiopatie nell'adulto con shunt destro e sinistro. E' tutto così semplice?

Adele Borghi

Cardiologia pediatrica e delle cardiopatie congenite

Ospedale dei Bambini

Spedali Civili - Brescia

Milano, 17/10/2012

LO SHUNT

- ❖ In condizioni normali il circolo sistemico e polmonare sono completamente separati ed in serie
- ❖ La presenza di una comunicazione anomala, a qualsiasi livello, comporta uno shunt
- ❖ Lo shunt può essere
 - sinistro-destro
 - bilanciato o bidirezionale
 - destro sinistrosecondo la direzione del flusso tra i due circuiti
- ❖ Uno shunt può essere isolato o essere parte di un complesso malformativo

FISIOPATOLOGIA

- ❖ Iperafflusso senza ipertensione polmonare ($QP/QS > 1$ - PAP=)
- ❖ Iperafflusso con ipertensione polmonare ($QP/QS > 1$ - PAP↑)
>>> (S.di Eisenmenger)
- ❖ Ipoafflusso polmonare con ipertensione polmonare ($QP/QS < 1$ - PAP↑)
- ❖ Ipoafflusso polmonare senza ipertensione polmonare ($QP/QS < 1$ - PAP=)

ANATOMIA

❖ Atriale

- PFO
- DIA
- RVAP

❖ Ventricolare

- DIV
- CAV

❖ Vascolare

- Dotto arterioso
- Fistole AV
- Collaterali veno-venosi

Le Linee Guida ESC 2010

Table 1 Classes of recommendations

Classes of recommendations	Definition
Class I	Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.
Class II	Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.
<i>Class IIa</i>	<i>Weight of evidence/opinion is in favour of usefulness/efficacy.</i>
<i>Class IIb</i>	<i>Usefulness/efficacy is less well established by evidence/opinion.</i>
Class III	Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.

Table 2 Levels of evidence

Level of evidence A	Data derived from multiple randomized clinical trials or meta-analyses.
Level of evidence B	Data derived from a single randomized clinical trial or large non-randomized studies.
Level of evidence C	Consensus of opinion of the experts and/or small studies, retrospective studies, registries.

PERVIETA' DEL FORAME OVALE

Variante fisiologica presente nel 20-25% della popolazione adulta

Profilassi delle recidive emboliche (ictus criptogenico) con terapia interventistica indicata in casi selezionati

Non indicata profilassi primaria

DIFETTO INTERATRIALE

❖ **Frequente in prima diagnosi**

❖ **Tipologia**

- Ostium secundum 80%
- Ostium primum 15%
- Seno venoso c.sup. 5%
- Seno venoso c.inf. <1%
- Seno cor. fenestrato <1%

DIFETTO INTERATRIALE

❖ Presentazione clinica e storia naturale

- Asintomatici fin oltre i 40 anni
- Ridotta tolleranza allo sforzo
- Aritmie
- Scompenso destro
- Infezioni polmonari
- Embolia paradossa (rara)

DIFETTO INTERATRIALE

❖ **Evoluzione e complicanze**

- Scompenso dx (tardivo)
- Aritmie (SV)
- Ipertensione polmonare (5%)
- Embolia paradossa (rara)

❖ **Indicazioni terapeutiche**

- Chiusura interventistica
- Chiusura chirurgica

DIA

Table 3 Indications for intervention in atrial septal defect

Indications	Class ^a	Level ^b
Patients with significant shunt (signs of RV volume overload) and PVR <5 WU should undergo ASD closure regardless of symptoms	I	B ²⁶
Device closure is the method of choice for secundum ASD closure when applicable	I	C
All ASDs regardless of size in patients with suspicion of paradoxical embolism (exclusion of other causes) should be considered for intervention	IIa	C
Patients with PVR ≥5 WU but <2/3 SVR or PAP <2/3 systemic pressure (baseline or when challenged with vasodilators, preferably nitric oxide, or after targeted PAH therapy) and evidence of net L–R shunt (Qp:Qs >1.5) may be considered for intervention	IIb	C
ASD closure must be avoided in patients with Eisenmenger physiology	III	C

Milano, 17/10/2012

DIA

Table 3 Indications for intervention in atrial septal defect

Indications	Class ^a	Level ^b
Patients with significant shunt (signs of RV volume overload) and PVR <5 WU should undergo ASD closure regardless of symptoms	I	B ²⁶
Device closure is the method of choice for secundum ASD closure when applicable	I	C
All ASDs regardless of size in patients with suspicion of paradoxical embolism (exclusion of other causes) should be considered for intervention	IIa	C
Patients with PVR ≥5 WU but <2/3 SVR or PAP <2/3 systemic pressure (baseline or when challenged with vasodilators, preferably nitric oxide, or after targeted PAH therapy) and evidence of net L–R shunt (Qp:Qs >1.5) may be considered for intervention	IIb	C
ASD closure must be avoided in patients with Eisenmenger physiology	III	C

Milano, 17/10/2012

DIA

Table 3 Indications for intervention in atrial septal defect

Indications	Class ^a	Level ^b
Patients with significant shunt (signs of RV volume overload) and PVR <5 WU should undergo ASD closure regardless of symptoms	I	B ²⁶
Device closure is the method of choice for secundum ASD closure when applicable	I	C
All ASDs regardless of size in patients with suspicion of paradoxical embolism (exclusion of other causes) should be considered for intervention	IIa	C
Patients with PVR ≥5 WU but <2/3 SVR or PAP <2/3 systemic pressure (baseline or when challenged with vasodilators, preferably nitric oxide, or after targeted PAH therapy) and evidence of net L-R shunt (Qp:Qs >1.5) may be considered for intervention	IIb	C
ASD closure must be avoided in patients with Eisenmenger physiology	III	C

Milano, 17/10/2012

DIA

Table 3 Indications for intervention in atrial septal defect

Indications	Class ^a	Level ^b
Patients with significant shunt (signs of RV volume overload) and PVR <5 WU should undergo ASD closure regardless of symptoms	I	B ²⁶
Device closure is the method of choice for secundum ASD closure when applicable	I	C
All ASDs regardless of size in patients with suspicion of paradoxical embolism (exclusion of other causes) should be considered for intervention	IIa	C
Patients with PVR ≥5 WU but <2/3 SVR or PAP <2/3 systemic pressure (baseline or when challenged with vasodilators, preferably nitric oxide, or after targeted PAH therapy) and evidence of net L-R shunt (Qp:Qs >1.5) may be considered for intervention	IIb	C
ASD closure must be avoided in patients with Eisenmenger physiology	III	C

Milano, 17/10/2012

DIFETTO INTERVENTRICOLARE

❖ Tipologia

- Perimembranoso 80%
 - ✓ Tipo CAV
 - ✓ Malallineato
 - ✓ Esteso
- Muscolare 15-20%
- Tratto efflusso 5%
 - ✓ Sopracrestale
 - ✓ Sottoarterioso
- Talora multipli
- Spesso presenti nelle c. complesse
- Postchirurgici

DIFETTO INTERVENTRICOLARE

❖ Presentazione clinica e storia naturale

- Shunt insignificante, VS e PAP normali (m. di Roger)
- Shunt significativo, VS poco dilatato, PAP normale o variamente aumentata (rari)
- Ampì, PAP e RVP elevate (Eisenmenger)
- Operati con shunt residuo

DIFETTO INTERVENTRICOLARE

❖ **Evoluzione e complicanze**

- Endocardite batterica
- Insufficienza aortica
- SPI (rara)
- Stenosi subaortica (rara)
- Aritmie

❖ **Indicazioni terapeutiche**

- Follow-up
- Chiusura chirurgica
- Chiusura interventistica (?)

DIFETTO INTERVENTRICOLARE

Table 4 Indications for intervention in ventricular septal defect

Indications	Class ^a	Level ^b
Patients with symptoms that can be attributed to L–R shunting through the (residual) VSD and who have no severe pulmonary vascular disease (see below) should undergo surgical VSD closure	I	C
Asymptomatic patients with evidence of LV volume overload attributable to the VSD should undergo surgical VSD closure	I	C
Patients with a history of IE should be considered for surgical VSD closure	IIa	C
Patients with VSD-associated prolapse of an aortic valve cusp causing progressive AR should be considered for surgery	IIa	C
Patients with VSD and PAH should be considered for surgery when there is still net L–R shunt ($Q_p:Q_s > 1.5$) present and PAP or PVR are $< 2/3$ of systemic values (baseline or when challenged with vasodilators, preferably nitric oxide, or after targeted PAH therapy)	IIa	C
Surgery must be avoided in Eisenmenger VSD and when exercise-induced desaturation is present	III	C
If the VSD is small, not subarterial, does not lead to LV volume overload or pulmonary hypertension, and if there is no history of IE, surgery should be avoided	III	C

DIFETTO INTERVENTRICOLARE

Table 4 Indications for intervention in ventricular septal defect

Indications	Class ^a	Level ^b
Patients with symptoms that can be attributed to L-R shunting through the (residual)VSD and who have no severe pulmonary vascular disease (see below) should undergo surgical VSD closure	I	C
Asymptomatic patients with evidence of LV volume overload attributable to the VSD should undergo surgical VSD closure	I	C
Patients with a history of IE should be considered for surgical VSD closure	IIa	C
Patients with VSD-associated prolapse of an aortic valve cusp causing progressive AR should be considered for surgery	IIa	C
Patients with VSD and PAH should be considered for surgery when there is still net L-R shunt (Qp:Qs >1.5) present and PAP or PVR are <2/3 of systemic values (baseline or when challenged with vasodilators, preferably nitric oxide, or after targeted PAH therapy)	IIa	C
Surgery must be avoided in Eisenmenger VSD and when exercise-induced desaturation is present	III	C
If the VSD is small, not subarterial, does not lead to LV volume overload or pulmonary hypertension, and if there is no history of IE, surgery should be avoided	III	C

Table 4 Indications for intervention in ventricular septal defect

Indications	Class ^a	Level ^b
Patients with symptoms that can be attributed to L-R shunting through the (residual)VSD and who have no severe pulmonary vascular disease (see below) should undergo surgical VSD closure	I	C
Asymptomatic patients with evidence of LV volume overload attributable to the VSD should undergo surgical VSD closure	I	C
Patients with a history of IE should be considered for surgical VSD closure	IIa	C
Patients with VSD-associated prolapse of an aortic valve cusp causing progressive AR should be considered for surgery	IIa	C
Patients with VSD and PAH should be considered for surgery when there is still net L-R shunt (Qp:Qs >1.5) present and PAP or PVR are <2/3 of systemic values (baseline or when challenged with vasodilators, preferably nitric oxide, or after targeted PAH therapy)	IIa	C
Surgery must be avoided in Eisenmenger VSD and when exercise-induced desaturation is present	III	C
If the VSD is small, not subarterial, does not lead to LV volume overload or pulmonary hypertension, and if there is no history of IE, surgery should be avoided	III	C

DIFETTO INTERVENTRICOLARE

Table 4 Indications for intervention in ventricular septal defect

Indications	Class ^a	Level ^b
Patients with symptoms that can be attributed to L–R shunting through the (residual) VSD and who have no severe pulmonary vascular disease (see below) should undergo surgical VSD closure	I	C
Asymptomatic patients with evidence of LV volume overload attributable to the VSD should undergo surgical VSD closure	I	C
Patients with a history of IE should be considered for surgical VSD closure	IIa	C
Patients with VSD-associated prolapse of an aortic valve cusp causing progressive AR should be considered for surgery	IIa	C
Patients with VSD and PAH should be considered for surgery when there is still net L–R shunt ($Q_p:Q_s > 1.5$) present and PAP or PVR are $< 2/3$ of systemic values (baseline or when challenged with vasodilators, preferably nitric oxide, or after targeted PAH therapy)	IIa	C
Surgery must be avoided in Eisenmenger VSD and when exercise-induced desaturation is present	III	C
If the VSD is small, not subarterial, does not lead to LV volume overload or pulmonary hypertension, and if there is no history of IE, surgery should be avoided	III	C

DOTTO DI BOTALLO

❖ Presentazione clinica e storia naturale

- Generalmente isolato
- Piccoli, VS e PAP normali
- Moderati, VS dilatato e PAP normale
- Moderati, VS normale e PAP elevata
- Ampì, VS normale, PAP elevata (Eisenmenger)

DOTTO DI BOTALLO

❖ **Evoluzione e complicanze**

- Disfunzione VS
- Scompenso
- Angina (anziano)
- Ipertensione polmonare
- Endoarterite batterica (??)

❖ **Indicazioni terapeutiche**

- Chiusura interventistica
- Chiusura chirurgica

DOTTO DI BOTALLO

Table 6 Indications for intervention in patent ductus arteriosus



Indications	Class ^a	Level ^b
PDA should be closed in patients with signs of LV volume overload	I	C
PDA should be closed in patients with PAH but PAP <2/3 of systemic pressure or PVR <2/3 of SVR	I	C
Device closure is the method of choice where technically suitable	I	C
PDA closure should be considered in patients with PAH and PAP >2/3 of systemic pressure or PVR >2/3 of SVR but still net L-R shunt (Qp:Qs >1.5) or when testing (preferably with nitric oxide) or treatment demonstrates pulmonary vascular reactivity	IIa	C
Device closure should be considered in small PDAs with continuous murmur (normal LV and PAP)	IIa	C
PDA closure should be avoided in silent duct (very small, no murmur)	III	C
PDA closure must be avoided in PDA Eisenmenger and patients with exercise-induced lower limb desaturation	III	C

Milano, 17/10/2012

DOTTO DI BOTALLO

Table 6 Indications for intervention in patent ductus arteriosus

Indications	Class ^a	Level ^b
PDA should be closed in patients with signs of LV volume overload	I	C
PDA should be closed in patients with PAH but PAP <2/3 of systemic pressure or PVR <2/3 of SVR	I	C
Device closure is the method of choice where technically suitable	I	C
PDA closure should be considered in patients with PAH and PAP >2/3 of systemic pressure or PVR >2/3 of SVR but still net L-R shunt (Qp:Qs >1.5) or when testing (preferably with nitric oxide) or treatment demonstrates pulmonary vascular reactivity	IIa	C
Device closure should be considered in small PDAs with continuous murmur (normal LV and PAP)	IIa	C
PDA closure should be avoided in silent duct (very small, no murmur)	III	C
PDA closure must be avoided in PDA Eisenmenger and patients with exercise-induced lower limb desaturation	III	C



DOTTO DI BOTALLO

Table 6 Indications for intervention in patent ductus arteriosus

Indications	Class ^a	Level ^b
PDA should be closed in patients with signs of LV volume overload	I	C
PDA should be closed in patients with PAH but PAP <2/3 of systemic pressure or PVR <2/3 of SVR	I	C
Device closure is the method of choice where technically suitable	I	C
PDA closure should be considered in patients with PAH and PAP >2/3 of systemic pressure or PVR >2/3 of SVR but still net L-R shunt (Qp:Qs >1.5) or when testing (preferably with nitric oxide) or treatment demonstrates pulmonary vascular reactivity	IIa	C
Device closure should be considered in small PDAs with continuous murmur (normal LV and PAP)	IIa	C
PDA closure should be avoided in silent duct (very small, no murmur)	III	C
PDA closure must be avoided in PDA Eisenmenger and patients with exercise-induced lower limb desaturation	III	C

Table 6 Indications for intervention in patent ductus arteriosus

Indications	Class ^a	Level ^b
PDA should be closed in patients with signs of LV volume overload	I	C
PDA should be closed in patients with PAH but PAP <2/3 of systemic pressure or PVR <2/3 of SVR	I	C
Device closure is the method of choice where technically suitable	I	C
PDA closure should be considered in patients with PAH and PAP >2/3 of systemic pressure or PVR >2/3 of SVR but still net L-R shunt (Qp:Qs >1.5) or when testing (preferably with nitric oxide) or treatment demonstrates pulmonary vascular reactivity	IIa	C
Device closure should be considered in small PDAs with continuous murmur (normal LV and PAP)	IIa	C
PDA closure should be avoided in silent duct (very small, no murmur)	III	C
PDA closure must be avoided in PDA Eisenmenger and patients with exercise-induced lower limb desaturation	III	C

Conclusioni

- ❖ Nell'adulto la causa più comune di shunt è il DIA (compreso il CAV parziale)
- ❖ La presenza di shunt insignificante, con PAP normali non è un'indicazione all'intervento **(III)**
- ❖ La presenza di shunt S-D significativo con PAP normale indica la correzione, con o senza sintomi **(Ia/b)**
- ❖ La presenza di complicanze o eventi clinici correlati allo shunt indica la correzione, anche se lo shunt non è significativo **(IIa)**

Conclusioni

- ❖ L'ipertensione polmonare con fisiologia tipo Eisenmenger controindica l'intervento, indipendentemente dall'entità dello shunt **(III)**
- ❖ La presenza di shunt S-D significativo con PAP aumentate, ma RVP reversibili, mantiene l'indicazione selettiva **(IIa)**
- ❖ La recente introduzione di farmaci efficaci per l'ipertensione polmonare porterà verosimilmente all'adozione di protocolli diagnostico-terapeutici condivisi

Shunt e PAP elevata - Ipotesi di protocollo

QP/QS >1.5, RVPI <6 UWm², RVP/RVS <0.3

>>> **INTERVENTO**

QP/QS >1.5, RVPI tra 6 e 9 UWm², RVP/RVS tra 0.3 e 0.5

➤ **Test NO -** >>> Farmaci per 12 mesi e rivalutazione

➤ **Test NO +** >>> Farmaci per 6 mesi e rivalutazione

↓
✓ **Efficace** >>> **INTERVENTO**

↓
✓ **Non efficace** >>> Bosentan per 6 mesi e rivalutazione

GRAZIE

Milano, 17/10/2012